{"id":"physician-s-choice-of-endocrine-therapy","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Musculoskeletal pain"}]},"_chembl":{"chemblId":"CHEMBL3770173","moleculeType":"Small molecule","molecularWeight":"440.32"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This drug works by selectively targeting and blocking estrogen receptors in breast cancer cells, which can slow or stop the growth of these cells. By doing so, it can help to reduce the risk of cancer recurrence or slow the progression of the disease.","oneSentence":"Physician's Choice of Endocrine Therapy is a treatment that targets hormone receptors to prevent or slow the growth of cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:07.256Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer"}]},"trialDetails":[{"nctId":"NCT07391774","phase":"PHASE3","title":"Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-07-07","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8","enrollment":1978},{"nctId":"NCT05467891","phase":"PHASE2","title":"Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer","status":"RECRUITING","sponsor":"Oana Danciu","startDate":"2022-09-13","conditions":"Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":200},{"nctId":"NCT04576455","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-11-27","conditions":"Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer","enrollment":303},{"nctId":"NCT06380751","phase":"PHASE3","title":"Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-01","conditions":"Advanced Breast Cancer","enrollment":500},{"nctId":"NCT06979596","phase":"PHASE2","title":"A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-08-11","conditions":"Malignant Neoplasm","enrollment":250},{"nctId":"NCT06486883","phase":"PHASE2","title":"Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype","status":"RECRUITING","sponsor":"MedSIR","startDate":"2025-06-30","conditions":"Advanced Breast Cancer, Advanced Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma","enrollment":200},{"nctId":"NCT07432178","phase":"PHASE3","title":"CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-02-23","conditions":"Breast Cancer","enrollment":2288},{"nctId":"NCT04059484","phase":"PHASE2","title":"Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-10-22","conditions":"Breast Cancer Metastatic","enrollment":367},{"nctId":"NCT04961996","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-08-27","conditions":"Early Breast Cancer","enrollment":4170},{"nctId":"NCT06585969","phase":"PHASE3","title":"A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer","status":"WITHDRAWN","sponsor":"Danish Breast Cancer Cooperative Group","startDate":"2026-01-01","conditions":"Metastatic Breast Cancer, ER-positive Breast Cancer, Luminal B","enrollment":""},{"nctId":"NCT05306340","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2022-08-03","conditions":"Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer","enrollment":373},{"nctId":"NCT06970912","phase":"PHASE2","title":"ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-08-01","conditions":"Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer, Early-Stage Breast Cancer","enrollment":393},{"nctId":"NCT05693766","phase":"PHASE2","title":"Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort","status":"RECRUITING","sponsor":"Sonya Reid","startDate":"2023-09-28","conditions":"Invasive Mammary Carcinoma, Metastatic Breast Cancer","enrollment":64},{"nctId":"NCT05826964","phase":"PHASE2","title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2023-06-12","conditions":"Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":24},{"nctId":"NCT07214532","phase":"NA","title":"Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Natera, Inc.","startDate":"2026-03","conditions":"Breast Neoplasms, Carcinoma, Ductal, Breast, Receptors, Estrogen (for ER-positive Requirement)","enrollment":725},{"nctId":"NCT04733118","phase":"PHASE2","title":"Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedSIR","startDate":"2021-08-05","conditions":"Early Breast Cancer","enrollment":393},{"nctId":"NCT05840211","phase":"PHASE3","title":"Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-05-08","conditions":"Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer","enrollment":654},{"nctId":"NCT07153757","phase":"PHASE3","title":"De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority Trial","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-09-01","conditions":"Breast Cancer Early Stage Breast Cancer (Stage 1-3)","enrollment":2934},{"nctId":"NCT07101159","phase":"PHASE2","title":"Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-09","conditions":"Early Breast Cancer, Adjuvant Therapy, Hormone Receptor Positive / HER2-negative Breast Cancer","enrollment":200},{"nctId":"NCT06643585","phase":"PHASE3","title":"A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse","status":"RECRUITING","sponsor":"Prof. Wolfgang Janni","startDate":"2025-04-22","conditions":"Breast Cancer","enrollment":180},{"nctId":"NCT03219476","phase":"PHASE2","title":"Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-02-05","conditions":"Breast Cancer, Invasive Breast Cancer","enrollment":37},{"nctId":"NCT06837792","phase":"PHASE2","title":"Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2023-10-01","conditions":"Hormone Receptor(HR)-Positive, Low HER2 Advanced Breast Cancer Patients (HER2 IHC 1+ or 2+ & ISH Negative)","enrollment":141},{"nctId":"NCT06882499","phase":"NA","title":"Stereotactic Ablative Body Radiotherapy (SABR) with Maintenance of Systemic Therapy Versus Physicians' Choice of Systemic Therapy for Oligoprogressive ER-positive, Her-2 Negative Breast Cancer II","status":"NOT_YET_RECRUITING","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2025-05-01","conditions":"Breast Cancer, Metastatic, Metastatic Breast Cancer","enrollment":74},{"nctId":"NCT06044623","phase":"PHASE3","title":"Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients","status":"RECRUITING","sponsor":"Region Örebro County","startDate":"2024-04-01","conditions":"Metastatic Breast Cancer, Advanced Breast Cancer, Quality of Life","enrollment":495},{"nctId":"NCT03503799","phase":"","title":"Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"North Eastern German Society of Gynaecological Oncology","startDate":"2018-07-17","conditions":"Primary Invasive Breast Cancer, Estrogen Receptor Positive Tumor, Human Epidermal Growth Factor Receptor 2 Negative Tumor","enrollment":1191},{"nctId":"NCT06656624","phase":"PHASE2","title":"Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-08-13","conditions":"Advanced Breast Cancer","enrollment":190},{"nctId":"NCT06375707","phase":"PHASE2","title":"Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-01-09","conditions":"Advanced Breast Cancer","enrollment":144},{"nctId":"NCT06339281","phase":"PHASE2","title":"A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Li Huiping","startDate":"2024-05-01","conditions":"Advanced Breast Cancer","enrollment":68},{"nctId":"NCT02448420","phase":"PHASE2","title":"Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2015-07","conditions":"Metastatic Breast Cancer","enrollment":73},{"nctId":"NCT06341621","phase":"PHASE3","title":"Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-04-02","conditions":"Breast Cancer","enrollment":1900},{"nctId":"NCT05891093","phase":"PHASE3","title":"Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-06-01","conditions":"Breast Cancer","enrollment":766},{"nctId":"NCT03772353","phase":"PHASE1, PHASE2","title":"Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2019-05-12","conditions":"Breast Cancer","enrollment":59},{"nctId":"NCT03184090","phase":"PHASE2","title":"Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC","status":"COMPLETED","sponsor":"MedSIR","startDate":"2017-06-28","conditions":"Metastatic Breast Cancer","enrollment":33},{"nctId":"NCT02598310","phase":"PHASE2","title":"Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer","status":"TERMINATED","sponsor":"Osaka Medical College","startDate":"2015-11","conditions":"Breast Cancer, Estrogen Receptor Negative Neoplasm, HER-2 Positive Breast Cancer","enrollment":30},{"nctId":"NCT03997539","phase":"PHASE2","title":"A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-08-15","conditions":"Metastatic Breast Cancer","enrollment":256},{"nctId":"NCT01419197","phase":"PHASE3","title":"A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-09","conditions":"Breast Cancer","enrollment":602},{"nctId":"NCT02238509","phase":"PHASE2","title":"Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies","status":"UNKNOWN","sponsor":"Consorzio Oncotech","startDate":"2014-11","conditions":"Metastatic Breast Cancer","enrollment":154}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Physician's Choice of Endocrine Therapy","genericName":"Physician's Choice of Endocrine Therapy","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Physician's Choice of Endocrine Therapy is a treatment that targets hormone receptors to prevent or slow the growth of cancer cells. Used for Treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}